이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!
Eris Lifesciences 대차 대조표 상태
재무 상태 기준 확인 2/6
Eris Lifesciences 의 총 주주 지분은 ₹32.2B 이고 총 부채는 ₹27.4B, 이는 부채 대 자기자본 비율을 84.9% 로 가져옵니다. 총자산과 총부채는 각각 ₹70.5B 및 ₹38.3B 입니다. Eris Lifesciences 의 EBIT는 ₹4.9B 이며 이자보상배율은 5.8 입니다. ₹14.0B 의 현금 및 단기 투자금을 보유하고 있습니다.
주요 정보
84.9%
부채 비율
₹27.35b
부채
| 이자 보상 비율 | 5.8x |
| 현금 | ₹14.01b |
| 주식 | ₹32.22b |
| 총 부채 | ₹38.27b |
| 총 자산 | ₹70.49b |
최근 재무 상태 업데이트
Eris Lifesciences (NSE:ERIS) Seems To Use Debt Quite Sensibly
Dec 07
Does Eris Lifesciences (NSE:ERIS) Have A Healthy Balance Sheet?
Nov 20These 4 Measures Indicate That Eris Lifesciences (NSE:ERIS) Is Using Debt Safely
Jun 20Recent updates
Eris Lifesciences Limited (NSE:ERIS) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?
May 24Why We're Not Concerned About Eris Lifesciences Limited's (NSE:ERIS) Share Price
May 10An Intrinsic Calculation For Eris Lifesciences Limited (NSE:ERIS) Suggests It's 25% Undervalued
Mar 14Analyst Estimates: Here's What Brokers Think Of Eris Lifesciences Limited (NSE:ERIS) After Its Third-Quarter Report
Feb 15Earnings Tell The Story For Eris Lifesciences Limited (NSE:ERIS)
Dec 28Eris Lifesciences (NSE:ERIS) Seems To Use Debt Quite Sensibly
Dec 07Are Eris Lifesciences Limited (NSE:ERIS) Investors Paying Above The Intrinsic Value?
Nov 11Are Eris Lifesciences Limited (NSE:ERIS) Investors Paying Above The Intrinsic Value?
Jul 20Does Eris Lifesciences (NSE:ERIS) Have A Healthy Balance Sheet?
Nov 20These 4 Measures Indicate That Eris Lifesciences (NSE:ERIS) Is Using Debt Safely
Jun 20A Look At The Fair Value Of Eris Lifesciences Limited (NSE:ERIS)
Feb 24Is Now The Time To Put Eris Lifesciences (NSE:ERIS) On Your Watchlist?
Dec 28Here's Why I Think Eris Lifesciences (NSE:ERIS) Might Deserve Your Attention Today
Sep 23If You Like EPS Growth Then Check Out Eris Lifesciences (NSE:ERIS) Before It's Too Late
May 26Eris Lifesciences Limited (NSE:ERIS) Shares Could Be 34% Above Their Intrinsic Value Estimate
Apr 17Eris Lifesciences Limited's (NSE:ERIS) Stock Has Fared Decently: Is the Market Following Strong Financials?
Mar 12Does Eris Lifesciences (NSE:ERIS) Deserve A Spot On Your Watchlist?
Feb 25Why Eris Lifesciences Limited (NSE:ERIS) Is A Dividend Rockstar
Feb 12Eris Lifesciences Limited (NSE:ERIS) Analysts Are Pretty Bullish On The Stock After Recent Results
Jan 30
Read This Before Buying Eris Lifesciences Limited (NSE:ERIS) Shares
Jan 17Our View On Eris Lifesciences' (NSE:ERIS) CEO Pay
Dec 30Is Eris Lifesciences Limited's (NSE:ERIS) Recent Performance Tethered To Its Attractive Financial Prospects?
Dec 10Eris Lifesciences (NSE:ERIS) Shareholders Booked A 25% Gain In The Last Year
Nov 23Is It Worth Buying Eris Lifesciences Limited (NSE:ERIS) For Its 1.1% Dividend Yield?
Oct 22How Does Eris Lifesciences' (NSE:ERIS) CEO Salary Compare to Peers?
Oct 01How Much Are Eris Lifesciences Limited (NSE:ERIS) Insiders Taking Off The Table?
Sep 14Investor Optimism Abounds Eris Lifesciences Limited (NSE:ERIS) But Growth Is Lacking
Aug 22Eris Lifesciences Limited (NSE:ERIS) Looks Interesting, And It's About To Pay A Dividend
Aug 08Should You Buy Eris Lifesciences Limited (NSE:ERIS) For Its Upcoming Dividend?
Aug 08재무 상태 분석
단기부채: ERIS 의 단기 자산 ( ₹23.0B )은 단기 부채( ₹25.3B ).
장기 부채: ERIS 의 단기 자산( ₹23.0B )이 장기 부채( ₹12.9B ).
부채 대 자본 내역 및 분석
부채 수준: ERIS 의 순부채 대 자기자본 비율( 41.4% )은 높음으로 간주됩니다.
부채 감소: ERIS 의 부채 대 자기자본 비율은 지난 5년간 15.1% 에서 84.9% 로 증가했습니다.
부채 범위: ERIS 의 부채는 영업 현금 흐름 ( 17.8% )에 의해 잘 갚지 않음입니다.
이자 보장: ERIS 의 부채에 대한 이자 지급은 EBIT( 5.8 x 적용 범위)로 잘 충당됩니다.